The Food and Drug Administration Thursday approved a new type of prostate cancer treatment from Dendreon Corp. The therapy, Provenge, is approved for certain men with advanced prostate cancer who have failed treatment with hormone therapy.
“The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” Karen Midthun, acting head of the FDA biologics center, said in a statement.
MarketClub has an interesting take on today’s DNDN action. Click Here for today’s FREE Trading Report + 100 score is given.
Huge profit for DNDN traders. Biotech stock high risk high return.